

Index

A

- Activin, multiple myeloma bone disease mediation, 109
- Acute myelogenous leukemia (AML), 73, 75, 93–99
- ADHR. *See* Autosomal dominant hypophosphatemic rickets
- Adiponectin, FGF23 regulation, 178
- Alkaline phosphatase, bone mineralization regulation, 19, 23
- α Klotho, 174–175, 177, 180
- AML. *See* Acute myelogenous leukemia
- Androgen receptor (AR)
 - knockout mouse, 33, 35
 - leukemia studies, 75
 - rheumatoid arthritis studies, 78
 - stem cell expression, 71–72
 - sympathetic nervous system control, 67–68
- AR. *See* Androgen receptor
- ARHR. *See* Autosomal recessive hypophosphatemic rickets
- Aromatase, deficient males, 28–29
- Autosomal dominant hypophosphatemic rickets (ADHR), 177, 180
- Autosomal recessive hypophosphatemic rickets (ARHR), 180
- Avascular necrosis of the femoral head (ANFH), 11

B

- B cell
 - bone loss mediation in ovariectomy mouse, 36
 - RANKL effects, 148–149
 - targeting in rheumatoid arthritis management, 157
- Bisphosphonates
 - bone metastasis, 136–137
 - multiple myeloma bone disease management, 115–116
- Bone lining cells, parathyroid hormone effects, 46–48
- Bone marrow. *See also* Hematopoiesis
 - neuronal regulation, 68–76, 93
 - niche
 - CXCL12-abundant reticular cell, 92–93
 - endosteal niche, 89
 - endothelial cell, 92
 - leptin receptor, 92
 - malignant cell interactions, 93–99
 - nestin-expressing mesenchymal stem cells, 92–93
 - osteoblast, 89–91
 - osteocyte, 91
 - perivascular niche, 91–92

- Bone metastasis. *See* Metastasis, bone
- Bortezomib, multiple myeloma bone disease management, 117

C

- Cadherins, breast cancer metastasis, 131
- Calcitonin gene-related peptide (CGRP),
 - sensory innervation of bone, 68
- Calcitriol, FGF23 regulation, 176
- CCL2, 134
- Central nervous system (CNS), skeletal homeostasis regulation, 64–67
- CGRP. *See* Calcitonin gene-related peptide
- Chronic kidney disease (CKD), FGF23 elevation, 181–182
- Chronic lymphocytic leukemia (CLL), 97
- Chronic myelogenous leukemia (CML), 73–75, 96, 98
- CKD. *See* Chronic kidney disease
- CLL. *See* Chronic lymphocytic leukemia
- CML. *See* Chronic myelogenous leukemia
- CNS. *See* Central nervous system
- Collagen, bone mineralization scaffold, 18
- CXCL12, 70, 72, 75, 91, 93–94, 98, 129, 159–160
- CXCL12-abundant reticular cell, 92–93, 145, 158
- CXCR4, 129

D

- DARC, 131
- Denosumab, 50, 117
- DKK1
 - disseminated tumor cell expression, 130, 132, 136
 - multiple myeloma bone disease osteoblast suppression mechanism, 112
- DMP1, 179

E

- EC. *See* Endothelial cell
- Endothelial cell (EC)
 - bone marrow niche, 92
 - signaling in bone production and destruction, 5–6
 - subtypes in bone, 3–5
 - vasculature development, 1–2
- Endothelin A (ET-1), antagonism for bone metastasis, 137
- ER. *See* Estrogen receptor

Index

- Estradiol
 gut microbiota and bone density, 212–214
 mediators of bone action
 humans, 31–32
 mouse versus human, 36–38
 menopause decrease, 29
- Estrogen receptor (ER)
 ER α -deficient males, 28–29
 knockout mouse, 33–36
- ET-1. *See* Endothelin A
- Exercise adaptation, osteocalcin role, 196,
 198–199
- F**
- Familial tumor calcinosis (FTC), 180–181
- FGF. *See* Fibroblast growth factor
- Fibroblast growth factor (FGF)
 angiogenesis and osteogenesis regulation, 9
- FGF23
 bone mineralization role, 17
 direct actions on bone, 175–176
 parathyroid effects, 175
 pathology
 autosomal dominant hypophosphatemic rickets, 180
 autosomal recessive hypophosphatemic rickets, 180
 chronic kidney disease, 181–182
 erythropoiesis elevation, 183–184
 familial tumor calcinosis, 180–181
 inflammation, 184
 left ventricular hypertrophy, 183
 McCune–Albright syndrome, 181
 osteoglophonic dysplasia, 181
 Raine syndrome, 181
 tumor-induced osteomalacia, 180
 X-linked hypophosphatemia, 180
 receptor, 172–173
 regulation
 acidosis, 178
 adipokines, 178
 α Klotho, 177
 calcitriol, 176
 calcium, 177
 hypoxia and inflammation, 177–178
 local regulation, 178–179
 parathyroid hormone, 176–177
 phosphate, 176
 renal effects, 173–175, 179–180
 structure, 171–172
 fracture repair, 11
- Follicle-stimulating hormone (FSH), menopause decrease, 28–29
- FOXO1, 199
- Fracture, vasculature in repair, 10–11
- FSH. *See* Follicle-stimulating hormone
- FTC. *See* Familial tumor calcinosis
- G**
- GACI. *See* Generalized arterial calcification in infancy
- GALNT, 179
- Generalized arterial calcification in infancy (GACI), 19
- GPRC6A, 194
- Gut microbiome
 bone density studies
 gut permeability and bone loss, 214–215
 mice, 209–211
 prebiotics, 218–219
 probiotics, 215–218
 sex steroid deficiency and bone loss, 212–214
 defining, 209
 immune function, 208
 model systems, 209
- H**
- Hematopoiesis
 overview, 87–89
 sympathetic regulation, 71–73
- Hematopoietic stem cell (HSC)
 dormancy, 131–133
 neuronal components of niche, 70
 osteimmunology, 158–160
- HIF. *See* Hypoxia-inducible factor
- HSC. *See* Hematopoietic stem cell
- Hypoxia-inducible factor (HIF)
 angiogenesis and osteogenesis regulation, 7–8
 FGF23 regulation, 177–178
 leukemia cell regulation in bone marrow niche, 94
 metastasis role, 135
- I**
- IGF-1. *See* Insulin-like growth factor 1
- IL-1. *See* Interleukin 1
- IL-3. *See* Interleukin 3
- IL-6. *See* Interleukin 6
- IL-7. *See* Interleukin 7
- Insulin, induction by osteocalcin, 192–194
- Insulin-like growth factor 1 (IGF-1)
 gut microbiota and bone density, 208, 210
 parathyroid hormone effects, 50
- Interleukin 1 (IL-1)
 mediation of estrogen effects on bone, 31
 parathyroid hormone effects, 50
- Interleukin 3 (IL-3), multiple myeloma bone disease mediation, 109
- Interleukin 6 (IL-6), blockade in rheumatoid arthritis management, 157

- Interleukin 7 (IL-7), multiple myeloma bone disease
osteoblast suppression mechanism,
111–112
- ITAM, 152
- L**
- LCN2. *See* Lipocalin-2
- Left ventricular hypertrophy (LVH), FGF23
elevation, 183
- Leptin
bone effects, 64
bone marrow cell expression of receptor, 92
- Leukemia stem cell (LSC), 73, 75, 96
- Lipocalin-2 (LCN2), appetite regulation, 199–201
- LSC. *See* Leukemia stem cell
- LVH. *See* Left ventricular hypertrophy
- M**
- Macrophage inflammatory protein 1 α (MIP1 α),
multiple myeloma bone disease
mediation, 108
- Matrix Gla protein (MGP), bone mineralization
inhibition, 20
- Matrix metalloproteinases (MMPs), osteolytic
metastasis role, 134
- MC4R, 200
- McCune–Albright syndrome, 181
- MDS. *See* Myelodysplasia
- MEPE, 179
- Mesenchymal stem cell (MSC), nestin expression,
92–93
- Metabolic acidosis, FGF23 regulation, 178
- Metastasis, bone
dormancy
clinical evidence, 130
immune system role, 132
stromal control, 130–132
survival-inducing cellular programs, 130
maintenance within bone, 129–130
osteoblastic metastasis, 136
osteolytic metastasis mediators, 134–136
outgrowth triggering, 132–133
overview, 127–128
passive shedding and vascular entry, 128–129
primary tumor characteristics, 128
treatment, 136–137
- MGP. *See* Matrix Gla protein
- Microbiome. *See* Gut microbiome
- Microfold cell, 148
- Mineralization
composition of bone, 16
determinants
calcium and phosphate levels, 17–18
collagen scaffold, 18
inhibitors of mineralization, 18–20
intracellular regulators
enzymes, 20–21
matrix vesicle theory, 21–22
- MIP1 α . *See* Macrophage inflammatory protein 1 α
- MM. *See* Multiple myeloma
- MMPs. *See* Matrix metalloproteinases
- MPN. *See* Myeloproliferative neoplasm
- MSC. *See* Mesenchymal stem cell
- Multiple myeloma (MM)
bone disease
adhesive interactions with bone marrow stem
cells, 110–111
mediators
activin, 109
interleukin-3, 109
macrophage inflammatory protein 1 α , 108
osteoprotegerin, 107–108
RANKL, 107–108
semaphorin 4D, 109–110
tumor necrosis factor α , 108–109
osteoblast suppression mechanisms, 111–114
overview, 106–107
treatment
bisphosphonates, 115–116
bortezomib, 117
denosumab, 117
bone microenvironment effects on multiple
myeloma cells, 114–115
clinical features, 105–106
epidemiology, 105
Myelodysplasia (MDS), 95, 97–99
Myeloproliferative neoplasm (MPN), 75–76, 94–95
- N**
- Nestin, mesenchymal stem cell expression, 92–93
- Neuropeptide Y (NPY), bone effects, 66–67
- NFATc1, osteoclastogenesis role, 150–153
- NG2, perivascular cell expression, 5
- Notch
angiogenesis and osteogenesis regulation, 8–9
metastasis role, 133
- NPY. *See* Neuropeptide Y
- O**
- OCN. *See* Osteocalcin
- OPG. *See* Osteoprotegerin
- Osteoblast
appetite regulation via lipocalin-2, 199–201
bone marrow niche, 89–91
metastasis, 136
multiple myeloma bone disease suppression
mechanisms, 111–114
parathyroid hormone effects, 45–46

Index

- Osteocalcin (OCN)
bone resorption and activation, 196
exercise
adaptation role, 196, 198–199
muscle energy metabolism regulation, 196–198
functional overview, 192–193
 γ -carboxylation, 194–195
glucose metabolism regulation, 192–194
GPRC6A modulation in β cells, 194
- Osteoclast
parathyroid hormone effects, 49–50
RANKL role in differentiation
bone remodeling and cell–cell communication, 153–154
calcium flux, 151–152
negative regulators, 153
NFATc1 role, 150–153
overview, 144–145
signaling, 149–150
- Osteocyte
adiposity regulation, 202
bone marrow niche, 91
parathyroid hormone effects, 52–55
- Osteoglophonic dysplasia, 181
- Osteoporosis, vasculature dysregulation, 9–10
- Osteoprogenitor cell, parathyroid hormone effects, 48–49
- Osteoprotegerin (OPG), multiple myeloma bone disease mediation, 107–108
- P**
- Parasympathetic nervous system (PNS)
bone regulation, 68
immune regulation, 78
- Parathyroid hormone (PTH)
bone mineralization role, 17
FGF23 regulation, 176–177
gut microbiota and bone density, 208, 210
hematopoietic stem cell effects, 132
T-cell mediation of effects, 51–52
targets
bone lining cells, 46–48
osteoblast, 45–46
osteoclast, 49–51
osteocyte, 52–56
osteoprogenitor cells, 48–49
therapy, 43–44
- PDGF. *See* Platelet-derived growth factor
- PHEX, 17, 179
- PHOSPHO1, bone mineralization regulation, 20–22
- PIGF. *See* Placental growth factor
- Placental growth factor (PIGF), fracture repair, 11
- Platelet-derived growth factor (PDGF), perivascular cell expression of receptor, 5
- Plexin-A1, 154
- PNS. *See* Parasympathetic nervous system
- PP_i. *See* Pyrophosphate
- Prebiotics, bone density studies, 218–219
- Probiotics, bone density studies, 215–218
- PTH. *See* Parathyroid hormone
- Pyrophosphate (PP_i)
bone mineralization inhibition, 19
FGF23 regulation, 179
- R**
- RA. *See* Rheumatoid arthritis
- Raine syndrome, 181
- RANKL
bone destruction in rheumatoid arthritis, 154–155
cell sources, 145–146
immune function
B cell, 148–149
lymph nodes, 147
medullary thymic epithelial cells, 146–147
microfold cell, 148
T cell, 148
mediation of estrogen effects on bone, 32–33, 36–37
metastasis role, 129–130, 134–135
multiple myeloma bone disease mediation, 107–108
osteoclast differentiation role
bone remodeling and cell–cell communication, 153–154
calcium flux, 151–152
negative regulators, 153
NFATc1 role, 150–153
overview, 144–145
signaling, 149–150
parathyroid hormone effects, 49, 52, 54
- Regulatory T cell (Treg), rheumatoid arthritis role, 155–157
- Rheumatoid arthritis (RA)
bone destruction mechanisms
osteoclasts, 154–155
T cells, 155–157
neuronal modulation studies, 78
treatment, 157–158
- RUNX2, 136
- S**
- Schwachman–Diamond syndrome, 95
- Sclerostin, multiple myeloma bone disease osteoblast suppression mechanism, 112–113
- Sema4D. *See* Semaphorin 4D
- Semaphorin 4D (Sema4D), multiple myeloma bone disease mediation, 109–110
- Serotonin, bone effects, 65–66
- SIK2, 54
- SMPD3. *See* Sphingomyelin phosphodiesterase 3
- SNS. *See* Sympathetic nervous system

- SOST, parathyroid hormone effects in osteocytes, 52–54
- Sotanercept, 109
- SP. *See* Substance P
- Sphingomyelin phosphodiesterase 3 (SMPD3), bone mineralization regulation, 20–22
- Substance P (SP), sensory innervation of bone, 68
- Sympathetic nervous system (SNS)
bone marrow regulation
hematological malignancies, 73–76
hematopoiesis, 71–73, 93
bone remodeling regulation, 67–68
immune function, 76–78
- T**
- T cell
bone destruction in rheumatoid arthritis, 155–157
bone loss mediation in ovariectomy mouse, 36
metastatic cell dormancy role, 132
multiple myeloma bone disease effects, 115
parathyroid hormone mediation of bone effects, 51–52
RANKL effects, 148
- Testosterone, replacement therapy and bone in men, 29–31
- TGF- β . *See* Transforming growth factor β
- TIO. *See* Tumor-induced osteomalacia
- TNF- α . *See* Tumor necrosis factor α
- Transforming growth factor β (TGF- β)
metastasis role, 133–134
parathyroid hormone effects, 50
- Treg. *See* Regulatory T cell
- Tumor necrosis factor α (TNF- α)
blockade in rheumatoid arthritis management, 157
mediation of estrogen effects on bone, 31, 213–214
multiple myeloma bone disease mediation, 108–109, 111–112
- Tumor-induced osteomalacia (TIO), 180
- V**
- Vascular endothelial growth factor (VEGF)
coupling of angiogenesis and osteogenesis, 6–8
fracture repair, 10–11
multiple myeloma bone disease, 114–115
- Vasculature, bone
angiogenesis and osteogenesis regulation
fibroblast growth factors, 9
hypoxia-inducible factors, 7–8
Notch, 8–9
vascular endothelial growth factor, 6–7
avascular necrosis, 11
development, 1–2
dysregulation in aging and osteoporosis, 9–10
endothelial cell
signaling in bone production and destruction, 5–6
subtypes, 3–5
fracture repair, 10–11
vessels, 2–3
- VCAM1, metastasis role, 133
- VEGF. *See* Vascular endothelial growth factor
- Vitamin D, bone mineralization role, 17
- W**
- WNT
metastasis role, 133
parathyroid hormone signaling cross talk in osteoblasts, 46, 53
- X**
- XLH. *See* X-linked hypophosphatemia
- X-linked hypophosphatemia (XLH), 180
- XRK3F2, 110, 113

This is a free sample of content from Bone: A Regulator of Physiology.
[Click here](#) for more information on how to buy the book.